Immune checkpoint blockade, particularly anti-programmed cell death protein-1 (PD-1)/PD-1 ligand-1 immunotherapy, exhibits considerable promise in the management of diverse cancer types, encompassing GBM [10]. Here, PDCD1 is linked to glioblastoma.